Roche’s PD-L1 play­er Tecen­triq fails PhI­II for ovar­i­an can­cer

Roche’s hit-and-miss record on Tecen­triq has post­ed an­oth­er miss.

The phar­ma gi­ant re­port­ed this morn­ing that the PD-L1 check­point failed a Phase III tri­al for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER